Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lydia Visser

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
The Journal of Pathology|March 13, 2010
Heparin binding epidermal growth factor in renal ischaemia/reperfusion injuryGemma M Mulder, Willemijn N Nijboer, Marc A Seelen, et al.
Science Translational Medicine|April 25, 2014
Suppression of p21Rac signaling and increased innate immunity mediate remission in Crohn's diseaseKaushal Parikh, Lu Zhou, Rajesh Somasundaram, et al.
JCI Insight|November 25, 2016
Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patientsMonique Aj van Eijndhoven, Josée M Zijlstra, Nils J Groenewegen, et al.
Nature Communications|November 25, 2025
Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
Blood Advances|January 4, 2018
Lymphadenopathy driven by TCR-V<sub>γ</sub>8V<sub>δ</sub>1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndromeStefano Vavassori, Jacob D Galson, Johannes Trück, et al.
Leukemia|October 14, 2022
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAPJulia Driessen, Marie José Kersten, Lydia Visser, et al.
The Lancet. Haematology|May 2, 2026
Very early [<sup>18</sup>F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trialMartin Hutchings, Arjan Diepstra, Anna Sureda Balari, et al.
The Journal of Pathology|February 28, 2015
Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder?Philip M Kluin, Anton W Langerak, Jannetta Beverdam-Vincent, et al.
Journal of the National Cancer Institute|January 31, 2012
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroupsKevin Y Urayama, Ruth F Jarrett, Henrik Hjalgrim, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
The Journal of Pathology|March 13, 2010
Heparin binding epidermal growth factor in renal ischaemia/reperfusion injuryGemma M Mulder, Willemijn N Nijboer, Marc A Seelen, et al.
Science Translational Medicine|April 25, 2014
Suppression of p21Rac signaling and increased innate immunity mediate remission in Crohn's diseaseKaushal Parikh, Lu Zhou, Rajesh Somasundaram, et al.
JCI Insight|November 25, 2016
Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patientsMonique Aj van Eijndhoven, Josée M Zijlstra, Nils J Groenewegen, et al.
Nature Communications|November 25, 2025
Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
Blood Advances|January 4, 2018
Lymphadenopathy driven by TCR-V<sub>γ</sub>8V<sub>δ</sub>1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndromeStefano Vavassori, Jacob D Galson, Johannes Trück, et al.
Leukemia|October 14, 2022
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAPJulia Driessen, Marie José Kersten, Lydia Visser, et al.
The Lancet. Haematology|May 2, 2026
Very early [<sup>18</sup>F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trialMartin Hutchings, Arjan Diepstra, Anna Sureda Balari, et al.
The Journal of Pathology|February 28, 2015
Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder?Philip M Kluin, Anton W Langerak, Jannetta Beverdam-Vincent, et al.
Journal of the National Cancer Institute|January 31, 2012
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroupsKevin Y Urayama, Ruth F Jarrett, Henrik Hjalgrim, et al.
Pageof 8